Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyOscar Health pediatric preventive screening Covera…
    Ask Trek AI about this page
    CurrentOscar HealthPolicy AHS-G2006-Diabetes

    Pediatric Preventive Screening

    Customize your policy alerts

    Sign up for Oscar Health Policy AHS-G2006-Diabetes alerts

    Get alerted when Policy AHS-G2006-Diabetes changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines coverage stance and clinical guidance for laboratory-based preventive screening tests for individuals newborn through age 18 (excluding genetic newborn screening panels which are addressed separately). Affects providers submitting claims to Oscar Health for pediatric preventive screening services.

    Policy Summary
    PayerOscar Health
    PolicyPediatric Preventive Screening
    Policy CodePolicy AHS-G2006-Diabetes
    Change TypeNo material change
    Effective DateOct 1, 2026
    Last ReviewJun 16, 2026
    Next Review DateJun 16, 2026
    Key ActionEnsure services meet authorization and medical necessity guidelines and submit accurate documentation with applicable CPT/HCPCS procedure codes.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    newborn–18
    age range covered
    multipleguideline sources
    >=20procedure codes
    3.5 µg/dLBLRV cited
    6,9,12 & annually 2–6lead schedule

    Coverage Criteria for Pediatric Preventive Screening

    Newborn and routine pediatric screenings meeting criteria

    The following screenings MEET CRITERIA when applied per the described population and frequency:

    Newborn universal screens: Newborn screening panel meets criteria when it follows applicable federal and state law recommendations

    State-specific mandates apply; see Applicable State and Federal Regulations

    Newborn hyperbilirubinemia: Screening for hyperbilirubinemia for all newborns meets criteria
    Newborn congenital hypothyroidism: Screening using serum thyroxine (T4) and/or thyroid-stimulating hormone (TSH) for all newborns meets criteria
    Newborn sickle cell disease: Screening for sickle cell disease for all newborns meets criteria
    Lead screening (increased risk individuals): Blood lead screening meets criteria for individuals with increased risk at the following frequencies: one test at 6 months, one test at 9 months, one test at 12 months; then one test annually from age 2 through 6 years

    See Note 1 for CDC-defined risk factors

    Anemia screening: Hemoglobin or hematocrit determination meets criteria in any of the following situations: (a) for all individuals at 12 months of age; (b) for individuals ≥4 months who are at risk for iron deficiency

    See Note 2 for AAP-defined risk factors

    Tuberculosis (TB) screening: For individuals ≥1 month of age who are at increased risk of tuberculosis, TB screening meets criteria

    See Note 3 for AAP TB risk factors

    Dyslipidemia screening: Screening using a fasting lipid profile or a non-fasting non-HDL-C meets criteria in any of the following situations: (a) annually for children and adolescents at increased risk due to personal or family history; (b) once during ages 9–11 and once at 17 years of age

    See Note 4 for AAP/NLA risk factors and indications (including familial hypercholesterolemia)

    Coverage stance by guideline and risk

    Coverage follows evidence-based recommendations from cited authorities; specific screening decisions depend on age and risk factors as noted by guideline sources.

    USPSTF-supported screenings: Follow USPSTF recommendations where applicable (examples cited in policy include: Hepatitis B screening for at-risk adolescents/adults; Hepatitis C screening for adults 18–79; HIV screening for adolescents ≥15 and at-risk younger adolescents; syphilis screening in sexually active adolescents at increased risk; chlamydia and gonorrhea screening in sexually active women ≤24).

    References: USPSTF statements cited in policy.

    Screenings with insufficient evidence for universal pediatric screening: The USPSTF concludes insufficient evidence to support routine universal screening for several pediatric areas including: lipid disorders in children/adolescents ≤20 years, elevated blood lead levels in asymptomatic children 1–5 years, primary hypertension screening in asymptomatic children/adolescents, and iron deficiency anemia screening in children 6–24 months.

    AAP and other specialty guidance may recommend risk-based or age-specific screening despite USPSTF 'insufficient evidence' determinations.

    Risk-based screening: Certain screenings are recommended based on individual risk or clinical indications (examples: lead testing for children with increased risk per CDC/AAP guidance; HIV and Hepatitis B testing for those at high risk; lipid testing including Lp(a) measurement in youth with suspected or familial hypercholesterolemia per NLA).

    Newborn screening panels are not uniform nationwide. Each state determines the specific conditions included in its newborn screening program, and state-required tests may differ from the federal Recommended Uniform Screening Panel (RUSP). The policy recognizes that RUSP lists core and secondary conditions that many programs adopt, but implementation and mandated tests are set at the state level and therefore vary by jurisdiction.

    The policy reflects the USPSTF finding that evidence is insufficient to support routine universal screening for lipid disorders in children and adolescents ≤20 years. Consistent with USPSTF and family medicine guidance, the policy favors evidence-based, risk-targeted approaches rather than blanket universal lipid screening for all pediatric patients.

    Examples of pediatric screening areas the USPSTF has judged to have insufficient evidence for routine universal application include: screening for lipid disorders in children and adolescents ≤20 years; screening for elevated blood lead levels in asymptomatic children ages 1–5 years; screening for primary hypertension in asymptomatic children and adolescents; and screening for iron deficiency anemia in children ages 6–24 months.

    When the USPSTF labels evidence as insufficient, it means the balance of benefits and harms cannot be determined for routine, population-wide screening. For policy application, this implies that routine universal screening is not supported as a default; instead, testing should be guided by age-specific recommendations from pediatric authorities (for example, AAP/Bright Futures) and by individual or population risk factors. The policy therefore supports risk-based or targeted screening strategies for these conditions rather than routine universal testing.

    Procedure Codes, Thresholds, and Reference Values

    Applicable CPT/HCPCS Procedure Codes (group 1)CPT
    80061Lipid panel; must include cholesterol total (82465), HDL direct (83718), triglycerides (84478)
    82247Bilirubin; total
    82248Bilirubin; direct
    82465Cholesterol, serum or whole blood, total
    83020Hemoglobin fractionation and quantitation; electrophoresis (eg, A2, S, C, and/or F)
    83021Hemoglobin fractionation and quantitation; chromatography (eg, A2, S, C, and/or F)
    83655Lead
    83718Lipoprotein, direct measurement; high density cholesterol (HDL cholesterol)
    84439Thyroxine; free
    84443Thyroid stimulating hormone (TSH)
    1–10 of 13
    1/2
    Applicable CPT/HCPCS Procedure Codes (group 2)CPT | HCPCS
    86481Tuberculosis test, cell mediated immunity antigen response measurement; enumeration of gamma interferon-producing T-cells
    86580Skin test; tuberculosis, intradermal
    88720Bilirubin, total, transcutaneous
    S3620Newborn metabolic screening panel (includes test kit, postage and state-specified laboratory tests)
    BMI thresholds referenced for dyslipidemia risk — overweight and obesity percentile thresholds
    Overweight (pediatric)BMI ≥ 85th percentile and <95th percentile
    Obesity (pediatric)BMI ≥ 95th percentile
    Reference sourceAAP dyslipidemia risk factors (Bright Futures/AAP) as cited in policy
    LDL target for diabetes-associated dyslipidemia monitoring
    LDL cholesterol target (pediatric, diabetes)LDL ≤ 100 mg/dL
    Testing timingInitial lipid profile soon after diabetes diagnosis (preferably after glycemia improved and age ≥2 years); if LDL ≤100 mg/dL, repeat testing at 9–11 years or every 3 years as reasonable

    Provider Responsibilities and Billing Guidance

    Prior Authorization

    Authorization and medical necessity

    Services described in this policy are covered only when they meet authorization and medical necessity requirements for the procedure, diagnosis, and the member’s state of residence; coverage does not guarantee reimbursement and may be affected by member benefit documents and provider contracts.

    • Coverage decisions are subject to authorization and medical necessity criteria.
    • Other factors (legislative mandates, provider contracts, member benefit documents) may modify reimbursement determinations.
    Billing Rule

    Procedure code billing guidance

    Bill services using the applicable CPT or HCPCS codes listed in this policy for the specific laboratory tests performed; the policy names the procedure codes to use when filing claims.

    Background and Rationale

    Preventive screening in pediatrics aims to protect and promote health across newborns, children, and adolescents by detecting treatable conditions early and guiding appropriate interventions. The American Academy of Pediatrics’ Bright Futures periodicity schedule frames many age-specific laboratory recommendations (for example: newborn blood and bilirubin testing; anemia screening at 12 months with prior risk assessment at four months; lead risk assessment and testing at specified intervals when indicated; and dyslipidemia screening with targeted age windows and risk assessments). These guidance sources are used alongside USPSTF determinations to shape coverage and to prioritize risk-based screening where universal evidence is lacking.

    Key Definitions

    Adolescent definition — WHO age range for adolescence
    Adolescent (WHO definition)Any person between the age of 10 and 19 years
    ContextUsed as the policy's table of terminology defining age-related terms
    Blood Lead Reference Value (BLRV) definition — CDC-derived metric definition and context
    BLRV definitionA CDC-derived metric identifying children with blood lead levels higher than the 97.5th percentile of U.S. children's levels
    Current numeric valueUpdated BLRV = 3.5 µg/dL (CDC update May 14, 2021)
    Intended useUsed to identify children for whom testing, follow-up, and public health interventions should be prioritized
    Policy Summary
    PayerOscar Health
    PolicyPediatric Preventive Screening
    Policy CodePolicy AHS-G2006-Diabetes
    Change TypeNo material change
    Effective DateOct 1, 2026
    Last ReviewJun 16, 2026
    Next Review DateJun 16, 2026
    Key ActionEnsure services meet authorization and medical necessity guidelines and submit accurate documentation with applicable CPT/HCPCS procedure codes.
    SourceLink
    On This Page
    Coverage Criteria for Pediatric Preventive ScreeningProcedure Codes, Thresholds, and Reference ValuesProvider Responsibilities and Billing GuidanceBackground and RationaleKey Definitions

    Policy references CDC, AAP, AAFP, NLA recommendations for risk-based approaches.

    Specimen guidanceInitial testing may use nonfasting non-HDL-C with confirmatory fasting lipid panel
    Blood Lead Reference Value (BLRV) — numeric reference value cited
    Blood Lead Reference Value (BLRV)3.5 µg/dL
    Percentile basisRepresents the 97.5th percentile of blood lead levels among U.S. children per CDC update (May 14, 2021)
    Use in practiceMetric used to identify children with higher-than-most blood lead levels to prompt public health and clinical action
    • Include procedure codes listed under “VIII. Applicable CPT/HCPCS Procedure Codes” (e.g., 80061, 82465, 83718, 84478, 83655, 86481, 86580, 88720, S3620).
    • The lipid panel (80061) must include component codes 82465, 83718, and 84478 as described in the code list.
    Documentation Required

    Maintain accurate clinical and billing records

    Providers must submit accurate documentation of the services performed and ensure coding reflects the service rendered; retain source records that support medical necessity and the billed codes.

    • Documentation must follow industry-standard coding guidelines (CPT, HCPCS, ICD-10, NDC, DRG, CMS NCCI/CCI edits).
    • Accurate records may be requested to substantiate claims and reimbursement.
    Note

    Operational provider instructions

    Use operational best practices to ensure correct code selection, timely submission, and alignment with member benefit and contract rules to avoid delays or denials.

    • Verify member benefits and contract terms prior to claim submission.
    • Confirm lab panels are billed with the specific CPT/HCPCS codes listed in this policy.
    Documentation Required

    Required documentation and coding

    Submit claims with the supporting clinical documentation that demonstrates the indication, age/risk criteria, and frequency consistent with this policy when applicable (for example, lead testing schedules or one-time dyslipidemia windows).

    • Document the clinical indication and risk factors that justify testing per policy criteria (e.g., CDC/AAP lead risk factors, dyslipidemia risk or age windows).
    • For newborn metabolic screening, bill the appropriate newborn panel HCPCS (S3620) per state-specified tests.
    Billing Rule

    Claims must reference listed CPT/HCPCS codes

    Ensure each claim includes the applicable CPT/HCPCS procedure codes listed in the policy that correspond to the laboratory tests performed; failure to reference the listed codes may lead to processing errors.

    • Example codes: 80061 (lipid panel), 83655 (lead), 84443 (TSH), 88720 (transcutaneous bilirubin), S3620 (newborn metabolic screening panel).
    • Use component codes for bundled panels as specified (e.g., 80061 component requirements).
    Denial Risk

    Risk of denial or recoupment for coding errors

    Claims may be denied or subject to recoupment if coding/billing guidelines or current reimbursement policies (including CCI/NCCI edits) are not followed; accurate coding and documentation are required to support payment.

    • Noncompliance with industry-standard coding guidelines can result in denial or recovery of payment.
    • Follow CMS and CMS NCCI/CCI guidance where applicable.
    Note

    State or federal government policy precedence

    If a conflict exists between this policy and any applicable government policy (e.g., LCD, NCD, or state Medicaid), the government policy takes precedence and will be used to make coverage determinations.

    • Check applicable Medicare (CMS) and state Medicaid policies for updates that may supersede this policy.
    • Government policy precedence may result in different coverage/claims outcomes for affected members.